{"schema_version":"1","generated_at":"2026-10-29T07:07:04.122Z","data_as_of":null,"url":"https://www.findmykol.com/kol/cheryl-mcdonald","json_url":"https://www.findmykol.com/kol/cheryl-mcdonald/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"cheryl-mcdonald","name":"Cheryl McDonald","credential":"MD","specialty":"Infectious Disease","specialty_raw":"Infectious Disease","therapeutic_area":"Infectious Disease","therapeutic_areas":["Infectious Disease"],"institution":"Texas Center for Infectious Disease","institution_url":"https://www.findmykol.com/institution/texas-center-for-infectious-disease","city":"Fort Worth","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1013982511","openalex":"A5010850224"},"summary":"Cheryl McDonald is an Infectious Disease physician affiliated with Texas Center for Infectious Disease. OpenAlex indexes 38 publications with 2,576 citations (h-index 19).","overview":null,"focus":{"indications":[],"research_topics":["Infectious Disease"]},"scholarship":{"works_count":38,"cited_by_count":2576,"h_index":19,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":12,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1013982511","source":"payments"},"prescribing":{"data_year":2023,"areas_total":10,"areas_shown":3,"areas":[{"area":"Anti-infectives","share_pct":98.4,"classes_total":26,"classes":[{"class":"Human Immunoglobulin G","setting":"administered","share_pct":56.7,"drugs":[{"name":"Immune globulin","share_pct":100}],"max_beneficiaries":15},{"class":"Lipoglycopeptide Antibacterial","setting":"administered","share_pct":36.1,"drugs":[{"name":"Dalbavancin","share_pct":100}],"max_beneficiaries":15}]},{"area":"Nervous system","share_pct":0.4,"classes_total":5,"classes":[{"class":"SSRI","setting":"prescribed","share_pct":0.2,"drugs":[{"name":"Trazodone Hcl","share_pct":63.2},{"name":"Citalopram Hbr","share_pct":19.1},{"name":"Fluoxetine Hcl","share_pct":17.6}],"max_beneficiaries":null},{"class":"SNRI","setting":"prescribed","share_pct":0.1,"drugs":[{"name":"Duloxetine Hcl","share_pct":59.3},{"name":"Desvenlafaxine Succinate Er","share_pct":40.7}],"max_beneficiaries":null}]},{"area":"Respiratory","share_pct":0.3,"classes_total":3,"classes":[{"class":"beta2-Adrenergic Agonist","setting":"prescribed","share_pct":0.1,"drugs":[{"name":"Albuterol Sulfate Hfa","share_pct":68.2},{"name":"Proair Respiclick","share_pct":31.8}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":0.1,"drugs":[{"name":"Fluticasone Propionate","share_pct":66.7},{"name":"Symbicort","share_pct":33.3}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":96,"facility_pct":4},"source":"medicare"},"publications":{"total":43,"shown":5,"withheld":38,"matched_by":"OpenAlex author record","recent":[{"title":"Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial","year":2026,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(26)00307-7","status":"verified"},{"title":"P-369. Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study","year":2026,"journal":"Open Forum Infectious Diseases","source_url":"https://doi.org/10.1093/ofid/ofaf695.587","status":"verified"},{"title":"Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV","year":2025,"journal":"AIDS","source_url":"https://doi.org/10.1097/qad.0000000000004372","status":"verified"},{"title":"Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization","year":2023,"journal":"Annals of Internal Medicine","source_url":"https://doi.org/10.7326/m22-3350","status":"verified"},{"title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","year":2023,"journal":"The Lancet HIV","source_url":"https://doi.org/10.1016/s2352-3018(23)00258-8","status":"verified"}],"source":"works"},"similar":[{"name":"Vivek Ramarathnam","slug":"vivek-ramarathnam","institution":"Texas Center for Infectious Disease","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vivek-ramarathnam","json_url":"https://www.findmykol.com/kol/vivek-ramarathnam/profile.json"},{"name":"Thomas Walsh","slug":"thomas-walsh","institution":"Cornell University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/thomas-walsh","json_url":"https://www.findmykol.com/kol/thomas-walsh/profile.json"},{"name":"Douglas Richman","slug":"douglas-richman","institution":"University of California San Diego","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/douglas-richman","json_url":"https://www.findmykol.com/kol/douglas-richman/profile.json"},{"name":"Vance Fowler","slug":"vance-fowler","institution":"Duke University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vance-fowler","json_url":"https://www.findmykol.com/kol/vance-fowler/profile.json"},{"name":"Myron Cohen","slug":"myron-cohen","institution":"University of North Carolina at Chapel Hill School of Medicine","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/myron-cohen","json_url":"https://www.findmykol.com/kol/myron-cohen/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":38}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}